PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Teerlink, John R.
TI  - Omecamtiv Mecarbil: Phase 2 Study Shows No Improvement in Dyspnea AHF But Trend for Further Exploration
DP  - 2013 Nov 01
TA  - MD Conference Express
PG  - 16--17
VI  - 13
IP  - 15
4099  - http://mdc.sagepub.com/content/13/15/16.short
4100  - http://mdc.sagepub.com/content/13/15/16.full
AB  - The Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure trial [ATOMIC-AHF; NCT01300013], was a Phase 2 dose ranging study which aimed to evaluate the safety, pharmacokinetics and pharmacodynamics, and efficacy of intravenous (IV) omecamtiv mecarbil (OM) in patients with acute heart failure (AHF). The investigators hypothesized that =1 dose of IV OM would be well tolerated and improve dyspnea in patients with left ventricular systolic dysfunction hospitalized for AHF.